Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.

Date publication

avril 2018

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel , Pr NOEL Georges

Tous les auteurs :
Paix A, Noel G, Falcoz PE, Levy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29706462

Résumé

Projections estimate an increase of 50% of the incidence of lung cancer by 2030. Early-stage non-small cell lung cancer represented 19% of NSCLC cases diagnosed in the US between 2005 and 2011. There is rising evidence in favour of lung cancer screening, which will reduce the occurrence of later-stage lung cancers while raising the incidence of early-stage NSCLC. Current guidelines state that for early-stage NSCLC, surgical resection should be performed, and stereotactic body radiotherapy (SBRT) is an option for patients who are non-medically operable. In this study, we compared the cost-effectiveness of SBRT with lobectomy in medically operable patients.

Mots clés

Cost-effectiveness analysis, Lobectomy, Non small cell lung cancer, Stereotactic body radiotherapy

Référence

Radiother Oncol. 2018 Apr 26;: